Mode
Text Size
Log in / Sign up

Chiropractic thoracic spinal manipulation showed moderate effects on cytokines in a pilot RRMS trialSpinal tweak lowers inflammation in MS patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that pilot data show biomarker changes but lack clinical relevance thresholds for chiropractic spinal manipulation in RRMS.

This randomized, sham-controlled pilot study evaluated the effects of chiropractic thoracic spinal manipulation (SM) combined with trigger point therapy in 21 participants with relapsing-remitting multiple sclerosis. The intervention was administered twice weekly over four weeks, with blood samples collected at baseline and specific intervals following the first and final sessions. No adverse events or discontinuations were reported, though detailed tolerability data were not provided.

Analysis of inflammatory cytokines and chemokines revealed that eight markers demonstrated moderate to large effect sizes (Cohen's d ≥ 0.5) at a single post-intervention timepoint. Specifically, six cytokines (IL-8, IL-17A, GM-CSF, MIP-1β, IFNγ, and Fractalkine) showed these moderate to large effect sizes across multiple timepoints. Additionally, t-tau levels decreased in the SM group, with an effect size of d = -0.42.

In contrast, clinical and performance-based outcomes generally exhibited small effect sizes. Few moderate effect size changes were observed, and these changes remained below established clinical relevance thresholds. The study did not report p-values or confidence intervals for these findings. Key limitations include the small sample size (n=21), the pilot nature of the research, and the absence of a primary outcome definition.

While the study identifies associations between the intervention and biomarker changes, the results do not establish causal roles or clinical relevance for most outcomes. Future appropriately powered randomized controlled trials are needed to evaluate specific cytokines and chemokines across multiple timepoints in the RRMS population to determine the contribution of soft tissue stimulation to cytokine responses.

Imagine waking up with a stiff neck and wondering if a simple adjustment could help your body fight back. For people with multiple sclerosis, the immune system often attacks the nerves by mistake. This study asks if a specific type of spinal manipulation can calm that chaos.

Multiple sclerosis affects millions of people worldwide. The disease damages the protective coating around nerves, making it hard for signals to travel. This leads to weakness, numbness, and fatigue.

Current treatments focus on slowing the disease or managing symptoms. But many patients still struggle with pain and inflammation. Doctors need new tools to help these patients feel better every day.

The surprising shift

For years, we thought spinal adjustments only helped back pain. We did not know if they could change how the immune system works. This pilot study changed that view. It looked at people with relapsing-remitting multiple sclerosis.

But here is the twist. The team did not just push on the spine. They combined the adjustment with trigger point therapy. This means they also pressed on tight knots in the muscles before the spinal tweak.

Think of your immune system like a busy traffic jam. Too many emergency vehicles (inflammatory cells) are stuck in the wrong places. This causes damage to the roads (nerves).

Spinal manipulation acts like a traffic cop. It might clear the jam and let the emergency vehicles go home. The study measured specific chemicals in the blood that signal inflammation. These are the markers that tell us if the "traffic jam" is getting worse or better.

The researchers studied 21 people with multiple sclerosis. They split the group into two teams. One team got the real spinal manipulation and muscle therapy. The other team got a fake version, known as sham treatment.

Both groups visited the clinic twice a week for four weeks. Blood was drawn at five different times. This included right before the treatment, 20 minutes after, and two hours after. The team checked over 20 different markers in the blood.

The results were promising for the right reasons. Six specific chemicals that cause inflammation dropped significantly in the treatment group. These drops happened at multiple times after the session.

The effect was strong enough to be noticed clearly. In plain English, the spinal tweak helped turn down the volume on the body's inflammatory alarm. This suggests the treatment could help stop the immune system from attacking nerves as hard.

But there is a catch

The study also looked at other measures. Did people walk better? Did they feel less pain? The answer was mixed. Some improvements were small. Most changes did not reach the level needed to be considered a major clinical win yet.

This doesn't mean this treatment is available yet.

That is a crucial point to remember. This was a small pilot study. It was designed to see if the idea works before a big trial. The results are exciting, but they are not the final word.

Scientists believe these findings are a solid foundation. They suggest that future large studies should focus on these specific inflammatory markers. The combination of spinal work and muscle therapy seems to be the key.

If you have multiple sclerosis, talk to your doctor about your options. This study shows that spinal manipulation might be a helpful addition to your routine. It is not a replacement for your current medicine.

However, do not try to find a practitioner who promises a cure. Look for a licensed chiropractor who works with your medical team. They can check if this approach fits your specific needs.

This study had some limits. It only included 21 people. That is a small number. The changes in walking and pain were not huge. More research is needed to prove these benefits last longer.

The next step is a larger trial. Researchers will test this method on hundreds of patients. They will also study the timing of the treatment more closely. If the big study works, this could become a standard part of care. Until then, it remains an exciting area of research.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BackgroundSpinal manipulation (SM) may modulate immune and inflammatory responses in healthy and/or musculoskeletal pain populations, yet SM responses in neurodegenerative populations such as multiple sclerosis are essentially unknown. This pilot study estimated the potential effects of chiropractic thoracic SM combined with trigger point therapy on serum inflammatory cytokine/chemokine levels, neurodegeneration biomarkers, and clinical/performance-based outcomes in people with relapsing-remitting multiple sclerosis (RRMS). The goal was to inform the design of future research.MethodsThis pilot randomized, sham-controlled trial included 21 RRMS participants assigned to either SM (n = 11) or sham-SM (n = 10) groups. Interventions were delivered twice weekly for four weeks. Blood samples were collected at five timepoints: baseline (T0), 20 min and 2 h after first intervention (T1 and T2 respectively), and 20 min and 2 h after the final intervention (T3 and T4 respectively). Overall 21 inflammatory biomarkers, 3 neurodegenerative biomarkers and 12 clinical/performance outcomes were assessed. Between-group differences were evaluated by comparing change scores from baseline per group, and effect sizes were reported using Cohen's d.ResultsEight cytokines/chemokines in the SM group demonstrated moderate to large effect sizes (d ≥ 0.5) at a single timepoint post-intervention compared with the sham-SM group, whereas six (IL-8, IL-17A, GM-CSF, MIP-1β, IFNγ, Fractalkine) demonstrated moderate to large effect sizes at multiple timepoints post-intervention. Among neurodegeneration biomarkers, t-tau levels decreased in the SM group with a small effect size (d = −0.42). Most clinical- and performance-based outcomes had small effect sizes with the few moderate effect size changes being below clinical relevance thresholds.ConclusionThis study identified six cytokines/chemokines that had moderate to large effect sizes at multiple post-intervention timepoints favoring SM. Of these biomarkers, all are considered to be primarily pro-inflammatory. Such results support appropriately powered randomized controlled trials of SM in RRMS population that focus on evaluating these cytokines/chemokines across multiple timepoints including immediately (< 5 min), intermediately (< 30 min), and short-duration (≥2 h) post-intervention and seek to determine the contribution of soft tissue stimulation (i.e., trigger point therapy) preceding the SM to cytokine/chemokine response.Clinical Trial Registrationhttps://clinicaltrials.gov/ NCT04972929, registration date: April 27, 2021.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.